Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
SCYNEXIS INC issued 34,750,000 shares of common stock, 8,750,000 pre-funded warrants to purchase common stock, and 43,500,000 common warrants to purchase common stock (each common of unit to institutional and accredited investors including Great Point Partners, LLC, Squadron Capital Management LLC, Adage Capital Management, L.P., Propel Bio Partners, a large healthcare-dedicated fund, and David Angulo, the Company's President and CEO for Combined purchase price of $0.92 per common share and accompanying common warrant, and $0.9199 per pre-funded warrant and accompanying common warrant; total upf.
- Security
- unit
- Shares
- 34,750,000 shares of common stock, 8,750,000 pre-funded warrants to purchase common stock, and 43,500,000 common warrants to purchase common stock (each common
- Purchaser
- institutional and accredited investors including Great Point Partners, LLC, Squadron Capital Management LLC, Adage Capital Management, L.P., Propel Bio Partners, a large healthcare-dedicated fund, and David Angulo, the Company's President and CEO
- Consideration
- Combined purchase price of $0.92 per common share and accompanying common warrant, and $0.9199 per pre-funded warrant and accompanying common warrant; total upf
Exact text from the filing
Pursuant to the terms of the securities purchase agreement, the Company will issue an aggregate of (i) 34,750,000 shares of its common stock, $0.001 par value per share (the “Common Shares”), (ii) pre-funded warrants to purchase up to 8,750,000 shares of common stock (the “Pre-Funded Warrants”) and (iii) accompanying common warrants to purchase up to an aggregate 43,500,000 shares of common stock or pre-funded warrants in lieu thereof (the “Common Warrants”). The aggregate share issuance includes 108,695 Common Shares and accompanying Common Warrants that were sold to the Company’s President and Chief Executive Officer, Dr. David Angulo. Each Common Share (or Pre-Funded Warrant) will be accompanied by one Common Warrant. The Common Shares and accompanying Common Warrants were sold at a combined price of $0.92 per Common Share and accompanying Common Warrant, and 8,750,000 Pre-Funded Warrants and accompanying Common Warrants were sold at a combined price of $0.9199 per Pre-Funded Warran
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SCYNEXIS INC entered into Securities Purchase Agreement with certain new and existing institutional and accredited investors valued at approximately $40.0 million (effective 2026-03-30).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain new and existing institutional and accredited investors
- Value
- approximately $40.0 million
- Effective
- 2026-03-30
Exact text from the filing
On March 30, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain new and existing institutional and accredited investors (the “Investors”)
View on SEC.gov